person · Reporting owner

Moriarty John B

Disclosed activity across 6 companies

Tapewire entity: 36233
SEC CIK: 0001564621

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALEXION PHARMACEUTICALS, INC.ALXN · Entity 137086	EVP & General Counsel	February 06, 2018	February 08, 2018
Kardigan, Inc.KARD · Entity 4569	Chief Legal Officer	June 17, 2026	June 22, 2026
Olema Pharmaceuticals, Inc.OLMA · Entity 613	EVP, Ch. Legal Officer & Sec.	February 01, 2023	February 02, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALEXION PHARMACEUTICALS, INC.

Report date February 06, 2018 · Filed February 08, 2018

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $.0001 per shareSEC Table I · non-derivative	Direct	74,537	Ending reported balance After 2018-02-08 transaction · row 4 4 source rows · reconciled sequence Row 1 · 2018-02-06 · Grant · Acquired 21,489 · Balance 71,400 F1: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. Row 2 · 2018-02-06 · Grant · Acquired 6,500 · Balance 77,900 F2: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 6,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary. Row 3 · 2018-02-08 · Sale · Disposed 2,163 · Balance 75,737 F3: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $115.20 - $116.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Row 4 · 2018-02-08 · Sale · Disposed 1,200 · Balance 74,537 F3: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F5: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.25 - $117.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Filing footnotes · ownership attribution and instrument terms

F1: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary.

F2: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 6,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary.

F3: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units.

F4: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $115.20 - $116.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

F5: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.25 - $117.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price.

Kardigan, Inc.

Report date June 17, 2026 · Filed June 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	47,784	Reported balance After 2026-06-17 transaction · row 1 1 source row Row 1 · 2026-06-17 · Grant · Acquired 47,784 · Balance 47,784 F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date.

Olema Pharmaceuticals, Inc.

Report date February 01, 2023 · Filed February 02, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.87 · Expires 2033-01-31	Direct	150,000	Reported balance After 2023-02-01 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-01 · Grant · Acquired 150,000 · Balance 150,000 F1: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Avidity Biosciences, Inc.

Report date February 27, 2026 · Filed February 27, 2026

Section 16 reporting ended · disclosed 2026-02-27. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2026-02-27 transaction · row 1 1 source row Row 1 · 2026-02-27 · Disposition to issuer · Disposed 92,054 · Balance 0 F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.42 · Expires 2035-01-05	Direct	Reported balance After 2026-02-27 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-27 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $44.57 · Expires 2034-07-31	Direct	Reported balance After 2026-02-27 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-02-27 · Disposition to issuer · Disposed 160,000 · Balance 0 F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

Filing footnotes · ownership attribution and instrument terms

F1: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer.

F2: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 24, 2024

Section 16 reporting ended · disclosed 2024-01-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Ending reported balance After 2024-01-23 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-01-23 · Disposition to issuer · Disposed 675 · Balance 71,660 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Row 2 · 2024-01-23 · Disposition to issuer · Disposed 71,660 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.
Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $45.88 · Expires 2033-05-01	Direct	0	Reported balance After 2024-01-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-01-23 · Disposition to issuer · Disposed 83,525 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS.

F2: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes.

F3: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU.

F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting).

PORTOLA PHARMACEUTICALS INC

Report date July 02, 2020 · Filed July 02, 2020

Section 16 reporting ended · disclosed 2020-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2020-07-02 transaction · row 1 1 source row Row 1 · 2020-07-02 · Disposition to issuer · Disposed 12,893 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2020-07-02 · Disposition to issuer · Disposed 48,750 · Balance 0 F2: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").
Performance Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2020-07-02 · Disposition to issuer · Disposed 24,375 · Balance 0 F3: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	Reported balance After 2020-07-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-02 · Disposition to issuer · Disposed 65,000 · Balance 0 F4: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.79 · Expires 2030-01-30	Direct	Reported balance After 2020-07-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-02 · Disposition to issuer · Disposed 32,500 · Balance 0 F5: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-07-02 · Disposition to issuer · Disposed 96,874 · Balance 0 F6: In connection with the Merger, these options were accelerated and canceled without payment.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	Reported balance After 2020-07-02 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-07-02 · Disposition to issuer · Disposed 37,083 · Balance 0 F7: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes.

F2: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio").

F3: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time.

F4: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F5: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law.

F6: In connection with the Merger, these options were accelerated and canceled without payment.

F7: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 17, 2026 Filed Jun 22, 2026 23:23 UTC	Kardigan, Inc. KARD · Entity 4569	GrantCommon Stock	47,784	$0.00	$0.00	Disclosure SEC source: 0001193125-26-277933 · ownership.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,784 F1 · kind: Each share is represented by a restricted stock unit ("RSU"). Each RSU represents a contingent right to receive one share of the Issuer's Common Stock upon settlement. The RSUs vest in full on June 17, 2028, subject to the Reporting Person's continuous service as of the applicable vesting date. Read SEC document
February 27, 2026 Filed Feb 27, 2026 20:17 UTC	Avidity Biosciences, Inc. RNAM · Entity 11854	Disposition to issuerStock Option (Right to Buy) · Derivative	160,000	Not disclosed Strike: $44.57	Not disclosed	Disclosure SEC source: 0001193125-26-082268 · ownership.xml · derivative · entry 3 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 160,000 shares Expires 2034-07-31 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document
February 27, 2026 Filed Feb 27, 2026 20:17 UTC	Avidity Biosciences, Inc. RNAM · Entity 11854	Disposition to issuerStock Option (Right to Buy) · Derivative	50,000	Not disclosed Strike: $31.42	Not disclosed	Disclosure SEC source: 0001193125-26-082268 · ownership.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · price: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. F2 · derivative.exercise_date: The reported Options were disposed of, pursuant to the Merger Agreement, in exchange for a cash payment equal to the excess of the merger consideration of $72.00 over the exercise price. Read SEC document
February 27, 2026 Filed Feb 27, 2026 20:17 UTC	Avidity Biosciences, Inc. RNAM · Entity 11854	Disposition to issuerCommon Stock	92,054	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-082268 · ownership.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. F1 · price: The reported securities represent shares of Common Stock (inclusive of shares of Common Stock issuable upon settlement of previously reported restricted stock units) disposed of pursuant to the terms of the Agreement and Plan of Merger, dated as of October 25, 2025 (the "Merger Agreement"), among Novartis AG ("Novartis"), Ajax Acquisition Sub, Inc., an indirect wholly owned subsidiary of Novartis, and the Issuer. Read SEC document
January 07, 2026 Filed Jan 9, 2026 22:12 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	SaleCommon Stock	2,374	$72.23	$171,474.02	Disclosure SEC source: 0001599901-26-000011 · wk-form4_1767996774.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,557 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on January 6, 2026 and the sale of the resulting shares of common stock on January 7, 2026. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. Read SEC document
December 17, 2025 Filed Dec 19, 2025 13:26 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	Tax withholdingCommon Stock	26,824	$71.87	$1,927,840.88	Disclosure SEC source: 0001599901-25-000217 · wk-form4_1766150765.xml · nonDerivative · entry 2 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,931 F2 · shares: Represents the number of shares withheld by the Issuer to cover tax withholding in connection with the settlement of PSUs on December 17, 2025. Read SEC document
December 17, 2025 Filed Dec 19, 2025 13:26 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantCommon Stock	56,000	$0.00	$0.00	Disclosure SEC source: 0001599901-25-000217 · wk-form4_1766150765.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,755 F1 · shares: Represents shares acquired upon the vesting of performance-based restricted stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer's common stock. The PSUs were originally granted to the Reporting Person on October 30, 2024. The PSUs were accelerated and settled on December 17, 2025 for tax planning purposes and such shares remain subject to recoupment by the Issuer if the Reporting Person's employment is terminated by the Issuer for cause or by the Reporting Person without good reason. Read SEC document
August 04, 2025 Filed Aug 5, 2025 21:27 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	SaleCommon Stock	2,245	$36.21	$81,291.45	Disclosure SEC source: 0001599901-25-000138 · wk-form4_1754429224.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,755 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on August 1, 2025 and the sale of the resulting shares of common stock on August 4, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary trade by the Reporting Person. The Reporting Person has executed an instruction letter for the automatic sale of such "sell-to-cover" shares, intended to satisfy the affirmative defense conditions of Rule 10b5-1. F2 · price: This represents a weighted-average price. These shares were sold in multiple transactions at prices ranging from $35.92 to $36.21. The Reporting Person undertakes to provide the Issuer, any securityholder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document
January 06, 2025 Filed Jan 9, 2025 01:29 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $31.42	$0.00	Disclosure SEC source: 0001599901-25-000025 · wk-form4_1736386148.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-05 F2 · derivative.exercise_date: This option vests in 48 equal installments on each monthly anniversary of the grant date, until it is fully vested on January 6, 2029. Read SEC document
January 06, 2025 Filed Jan 9, 2025 01:29 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001599901-25-000025 · wk-form4_1736386148.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 F1 · shares: Represents restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of January 6, 2025, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
August 01, 2024 Filed Aug 5, 2024 13:11 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantStock Option (Right to Buy) · Derivative	160,000	$0.00 Strike: $44.57	$0.00	Disclosure SEC source: 0001599901-24-000123 · wk-form4_1722863507.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2034-07-31 F2 · derivative.exercise_date: 1/4th of the total number of shares subject to the options shall vest on the first anniversary of August 1, 2024 (the "Vesting Commencement Date"), and 1/48th of the total number of shares subject to the options shall vest on each monthly anniversary of the Vesting Commencement Date thereafter, subject to the Reporting Person's continuous service to the Issuer on each such vesting date, so that the options shall be fully vested on the fourth anniversary of the Vesting Commencement Date. Read SEC document
August 01, 2024 Filed Aug 5, 2024 13:11 UTC	Avidity Biosciences, Inc. RNA · Entity 11854	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001599901-24-000123 · wk-form4_1722863507.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs shall vest in four equal installments on the first four anniversaries of August 1, 2024, subject to the Reporting Person's continuous service to the Issuer on each such vesting date. Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerOption to Purchase Common Stock · Derivative	83,525	Not disclosed Strike: $45.88	Not disclosed	Disclosure SEC source: 0001140361-24-003540 · form4.xml · derivative · entry 3 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,525 shares Expires 2033-05-01 F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") that was outstanding and unexercised as of immediately prior to the Effective Time, whether or not vested, with a per share exercise price ("Per Share Exercise Price") that was less than the Closing Consideration, was cancelled and converted into the right to receive the sum of (A) a cash payment, without interest, equal to (x) the excess of (1) the Closing Consideration over (2) the Per Share Exercise Price, multiplied by (y) the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting) and (B) one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time (without regard to vesting). Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	71,660	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003540 · form4.xml · nonDerivative · entry 2 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F3 · price: Pursuant to the Merger Agreement, at the Effective Time, each of these restricted stock units ("RSUs") that was outstanding as of immediately prior to the Effective Time was cancelled and the Reporting Person was entitled to receive the Merger Consideration in respect of each such RSU. Read SEC document
January 23, 2024 Filed Jan 24, 2024 01:37 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Disposition to issuerCommon Stock	675	Not disclosed	Not disclosed	Disclosure SEC source: 0001140361-24-003540 · form4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,660 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 8, 2023, among the Issuer, Bristol-Myers Squibb Company ("BMS"), and Vineyard Merger Sub Inc., a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of January 23, 2024 (such date and time of such Merger, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of BMS. F2 · price: At the Effective Time, each issued and outstanding share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was converted into the right to receive (A) $58.00 per share in cash (the "Closing Consideration") and (B) one contingent value right (a "CVR"), which represents the right to receive the Milestone Payment (as such term is defined in the CVR Agreement, which is itself defined in the Merger Agreement) (the consideration contemplated by (A) and (B), together, the "Merger Consideration"), without interest and subject to any withholding taxes. Read SEC document
August 09, 2023 Filed Aug 10, 2023 20:22 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	GrantCommon Stock	22,297	$37.00	$824,989.00	Disclosure SEC source: 0001628280-23-028878 · wk-form4_1691698952.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,660 F1 · shares: Grant of Restricted Stock Units (RSUs). Shares will vest 100% on the one year anniversary of the grant date. Read SEC document
February 01, 2023 Filed Feb 2, 2023 22:34 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	150,000	$0.00 Strike: $4.87	$0.00	Disclosure SEC source: 0001209191-23-006291 · doc4.xml · derivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, Ch. Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2024 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
February 01, 2022 Filed Feb 4, 2022 00:05 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	166,250	$0.00 Strike: $7.02	$0.00	Disclosure SEC source: 0001415889-22-001057 · form4-02032022_040246.xml · derivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, CH. LEGAL OFFICER & SEC. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,250 Underlying: Common Stock · 166,250 shares Expires 2032-01-31 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on February 1, 2023 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
November 18, 2020 Filed Nov 19, 2020 23:57 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	161,406	$0.00 Strike: $19.00	$0.00	Disclosure SEC source: 0001209191-20-059523 · doc4.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · EVP, Ch. Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,406 Underlying: Common Stock · 161,406 shares Expires 2030-11-17 F2 · derivative.exercise_date: 25% of the shares subject to the option vest on November 18, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. Read SEC document
September 19, 2020 Filed Nov 19, 2020 23:57 UTC	Olema Pharmaceuticals, Inc. OLMA · Entity 613	GrantStock Option (Right to Buy) · Derivative	252,060	$0.00 Strike: $4.82	$0.00	Disclosure SEC source: 0001209191-20-059523 · doc4.xml · derivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, Ch. Legal Officer & Sec. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,060 Underlying: Common Stock · 252,060 shares Expires 2030-09-18 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on September 8, 2021 and 1/48 of the total number of shares subject to the option vest each month thereafter, subject to the Reporting Person's continuous service through each applicable vesting date. The stock option is early exercisable. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerRestricted Stock Units · Derivative	37,083	$0.00	$0.00	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · derivative · entry 7 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 37,083 shares Expires not disclosed F7 · derivative.exercise_price: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. F7 · derivative.exercise_date: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. F7 · derivative.expiration_date: At the Effective Time, each restricted stock unit ("Issuer RSU") was converted into a restricted stock unit, subject to substantially the same terms and conditions as were applicable to such Issuer RSU, with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer RSU by (ii) the Exchange Ratio. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	96,874	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · derivative · entry 6 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 96,874 shares Expires not disclosed F6 · derivative.exercise_price: In connection with the Merger, these options were accelerated and canceled without payment. F6 · price: In connection with the Merger, these options were accelerated and canceled without payment. F6 · derivative.exercise_date: In connection with the Merger, these options were accelerated and canceled without payment. F6 · derivative.expiration_date: In connection with the Merger, these options were accelerated and canceled without payment. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	32,500	Not disclosed Strike: $12.79	Not disclosed	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · derivative · entry 5 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 32,500 shares Expires 2030-01-30 F5 · price: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F5 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options became fully vested (assuming performance at target), canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that were subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerStock Option (Right to Buy) · Derivative	65,000	$5.21 Strike: $12.79	$338,650.00	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · derivative · entry 4 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 65,000 shares Expires 2030-01-30 F4 · price: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. F4 · derivative.exercise_date: At the Effective Time, each of these unvested and outstanding options was accelerated, canceled and converted into the right to receive a cash amount equal to the product of (i) the number of shares that are subject to such options and (ii) $18.00 less the applicable exercise price per share of such options, subject to any applicable withholding or other taxes required by applicable law. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerPerformance Stock Units · Derivative	24,375	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · derivative · entry 3 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,375 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. F3 · price: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. F3 · derivative.exercise_date: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. F3 · derivative.expiration_date: In connection with the Merger, these performance restricted stock units were canceled without payment immediately prior to the Effective Time. Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerPerformance Stock Units · Derivative	48,750	$0.00	$0.00	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,750 shares Expires not disclosed F2 · derivative.exercise_price: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio"). F2 · derivative.exercise_date: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio"). F2 · derivative.expiration_date: Immediately prior to the Effective Time, each performance restricted stock unit ( "Issuer PSU") was converted into a restricted stock unit with respect to the number of shares of Alexion common stock determined by multiplying (i) the total number of shares subject to such Issuer PSU by (ii) an exchange ratio equal to $18.00 divided by $112.39 (the "Exchange Ratio"). Read SEC document
July 02, 2020 Filed Jul 2, 2020 16:35 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Disposition to issuerCommon Stock	12,893	$18.00	$232,074.00	Disclosure SEC source: 0001209191-20-040346 · doc4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · acquired: Pursuant to the Agreement and Plan of Merger, dated as of May 5, 2020, by and among Portola Pharmaceuticals, Inc. (the "Issuer"), Alexion Pharmaceuticals, Inc. ("Alexion") and Odyssey Merger Sub Inc. ("Merger Sub") (the "Merger Agreement"), on July 2, 2020, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a direct, wholly owned subsidiary of Alexion (the "Merger"). At the effective time of the Merger (the "Effective Time"), these shares were canceled in exchange for $18.00 per share in cash, without interest and subject to any applicable withholding taxes. Read SEC document
March 02, 2020 Filed Mar 3, 2020 18:58 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	4,327	$9.68	$41,885.36	Disclosure SEC source: 0001209191-20-015665 · doc4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,976 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). F2 · balance_after: Includes 1,119 shares acquired under the Issuer's employee stock purchase plan on February 28, 2020. Read SEC document
February 24, 2020 Filed Feb 26, 2020 20:26 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantPerformance Stock Unit · Derivative	73,125	$0.00	$0.00	Disclosure SEC source: 0001209191-20-013274 · doc4.xml · derivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,125 Underlying: Common Stock · 73,125 shares Expires 2023-02-24 F1 · derivative.exercise_price: Each performance stock unit (PSU) represents a contingent right to receive one (1) share of the Issuer's common stock. F2 · derivative.exercise_price: One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F3 · derivative.exercise_price: One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F4 · derivative.exercise_price: One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F2 · derivative.exercise_date: One-third of the PSUs will be earned one or after the one (1) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 50% per share from the grant date closing price of Issuer's Common Stock on the Nasdaq Global Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F3 · derivative.exercise_date: One-third of the PSUs will be earned on or after the two (2) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 100% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (20) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F4 · derivative.exercise_date: One-third of the PSUs will be earned on the three (3) year anniversary of the grant date of February 24, 2020 and when the average closing price of the Issuer's Common Stock on the Nasdaq Global Select Market appreciates 150% per share from the grant date closing price of the Issuer's Common Stock on the Nasdaq Global Select Market over a period of twenty (2) consecutive trading days. The closing price of the Issuer's Common Stock on the Nasdaq Global Market on February 24, 2020 was $13.06. F5 · derivative.expiration_date: Any PSUs not yearned on the three (3) year anniversary of the grant date will expire. Read SEC document
February 03, 2020 Filed Feb 4, 2020 19:03 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	3,544	$12.89	$45,682.16	Disclosure SEC source: 0001209191-20-006663 · doc4.xml · nonDerivative · entry 2 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,184 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 31, 2020 Filed Feb 4, 2020 19:03 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	65,000	$0.00 Strike: $12.79	$0.00	Disclosure SEC source: 0001209191-20-006663 · doc4.xml · derivative · entry 3 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2030-01-30 F3 · derivative.exercise_date: The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2020, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document
January 31, 2020 Filed Feb 4, 2020 19:03 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	16,250	$0.00	$0.00	Disclosure SEC source: 0001209191-20-006663 · doc4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,728 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs vest in three equal annual installments subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each vest date. Read SEC document
March 04, 2019 Filed Mar 5, 2019 18:30 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	Tax withholdingCommon Stock	4,297	$33.42	$143,605.74	Disclosure SEC source: 0001209191-19-016983 · doc4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,952 F1 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of Performance Stock Units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. The sale is intended to comply with the requirements of Rule 10b5-1(c)(1)(i)(B) under the Exchange Act and be interpreted to meet the requirements of Rule 10b5-1(c). Read SEC document
January 31, 2019 Filed Feb 4, 2019 17:56 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	75,000	$0.00 Strike: $27.10	$0.00	Disclosure SEC source: 0001209191-19-006910 · doc4.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2029-01-30 F2 · derivative.exercise_date: The options shall vest as follows: 1/48th of the shares subject to the option shall vest each month after January 31, 2019, subject to the Reporting Person's Continuous Service as of each such date. Read SEC document
January 31, 2019 Filed Feb 4, 2019 17:56 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	18,750	$0.00	$0.00	Disclosure SEC source: 0001209191-19-006910 · doc4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,750 F1 · shares: Grant of Restricted Stock Units ("RSUs") in consideration of services rendered. The RSUs vest in three equal annual installments on January 31, 2020, January 31, 2021 and January 31, 2022, subject to Reporting Person's Continuous Service under the Issuer's plan documents as of each such date. Read SEC document
March 29, 2018 Filed Mar 30, 2018 17:24 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantStock Option (Right to Buy) · Derivative	125,000	$0.00 Strike: $32.66	$0.00	Disclosure SEC source: 0001209191-18-022235 · doc4.xml · derivative · entry 2 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Stock · 125,000 shares Expires 2028-03-28 F2 · derivative.exercise_date: The Option vests as follows: 25% of the shares shall vest one year from the Vesting Commencement Date of March 12, 2018, and the remaining shares shall vest ratably over the next 36 months. Read SEC document
March 29, 2018 Filed Mar 30, 2018 17:24 UTC	PORTOLA PHARMACEUTICALS INC PTLA · Entity 147987	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001209191-18-022235 · doc4.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2019, subject to Reporting Person's Continuous Service as of each such date. F1 · balance_after: Grant of Restricted Stock Units ("RSU") in consideration of services rendered. The RSU vests annually over three years commencing on March 1, 2019, subject to Reporting Person's Continuous Service as of each such date. Read SEC document
February 08, 2018 Filed Feb 8, 2018 19:16 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	1,200	$115.70	$138,840.00	Disclosure SEC source: 0000899866-18-000037 · wf-form4_151813537006905.xml · nonDerivative · entry 4 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,537 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $116.25 - $117.25. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 08, 2018 Filed Feb 8, 2018 19:16 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	2,163	$115.70	$250,259.10	Disclosure SEC source: 0000899866-18-000037 · wf-form4_151813537006905.xml · nonDerivative · entry 3 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,737 F3 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $115.20 - $116.20. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 06, 2018 Filed Feb 8, 2018 19:16 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	6,500	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000037 · wf-form4_151813537006905.xml · nonDerivative · entry 2 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,900 F2 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 6,500 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/4 of such shares vested on February 6, 2018 and 1/4 vest on each subsequent anniversary. Read SEC document
February 06, 2018 Filed Feb 8, 2018 19:16 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	21,489	$0.00	$0.00	Disclosure SEC source: 0000899866-18-000037 · wf-form4_151813537006905.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 71,400 F1 · shares: On February 6, 2018, the Leadership and Compensation Committee determined that the reporting person earned 21,489 Performance Share Units upon achievement of certain performance targets previously established by the Committee. 1/3 of such shares vested on February 6, 2018 and 1/3 vest on each subsequent anniversary. Read SEC document
February 05, 2018 Filed Feb 7, 2018 18:35 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	1,261	$117.26	$147,864.86	Disclosure SEC source: 0000899866-18-000015 · wf-form4_151804652977932.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,911 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. Read SEC document
March 01, 2017 Filed Mar 1, 2017 19:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	282	$132.50	$37,365.00	Disclosure SEC source: 0000899866-17-000060 · wf-form4_148841556728953.xml · nonDerivative · entry 3 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,672 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $132.00 - $132.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 28, 2017 Filed Mar 1, 2017 19:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantOption to Purchase Common Stock · Derivative	12,800	$0.00 Strike: $131.25	$0.00	Disclosure SEC source: 0000899866-17-000060 · wf-form4_148841556728953.xml · derivative · entry 5 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,800 Underlying: Common Stock, par value $.0001 per share · 12,800 shares Expires 2027-02-28 F5 · shares: Stock option award under 2004 Incentive Plan. 25% vest on the first anniversary of the grant date, 1/16 every three months thereafter until fully vested over 4 years. Read SEC document
February 28, 2017 Filed Mar 1, 2017 19:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	GrantCommon Stock, par value $.0001 per share	6,500	$0.00	$0.00	Disclosure SEC source: 0000899866-17-000060 · wf-form4_148841556728953.xml · nonDerivative · entry 4 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,172 F4 · shares: Award of Restricted Stock Units under the 2004 Incentive Plan. 25% vests on each anniversary of the grant date. Read SEC document
February 28, 2017 Filed Mar 1, 2017 19:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	910	$131.71	$119,856.10	Disclosure SEC source: 0000899866-17-000060 · wf-form4_148841556728953.xml · nonDerivative · entry 2 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,954 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 27, 2017 Filed Mar 1, 2017 19:46 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	612	$131.20	$80,294.40	Disclosure SEC source: 0000899866-17-000060 · wf-form4_148841556728953.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,864 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $131.00 - $131.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 09, 2017 Filed Feb 10, 2017 18:05 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	167	$126.84	$21,182.28	Disclosure SEC source: 0000899866-17-000036 · wf-form4_148676789017357.xml · nonDerivative · entry 1 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,476 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 07, 2017 Filed Feb 8, 2017 16:40 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	135	$128.09	$17,292.15	Disclosure SEC source: 0000899866-17-000029 · wf-form4_148659000596099.xml · nonDerivative · entry 3 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,643 F4 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Restricted Stock Units. F5 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $128.00 - $128.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document
February 06, 2017 Filed Feb 8, 2017 16:40 UTC	ALEXION PHARMACEUTICALS, INC. ALXN · Entity 137086	SaleCommon Stock, par value $.0001 per share	23	$126.38	$2,906.74	Disclosure SEC source: 0000899866-17-000029 · wf-form4_148659000596099.xml · nonDerivative · entry 2 Moriarty John B · CIK 0001564621 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,778 F1 · shares: This sale was made to cover withholding taxes immediately following the vesting of previously granted Performance Stock Units. F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $126.00 - $126.99. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of shares sold at each price. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.